Clinical Trials Directory

Trials / Unknown

UnknownNCT04959786

MANS-NRIZ Trial for COVID-19 Treatment : Extension Study

Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: Extension Study

Status
Unknown
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Mansoura University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This search will focus on patients with COVID 19 infection this study is a prospective cohort study based on the analysis of response in comparative panel between two arm Nitazoxanide, Ribavirin and Ivermectin plus Zinc arm and other arm without any intervention as regards the safety and efficacy and cost effective result. Two years duration of the project would be enough to cover the stages of the work as shown below in the time plan. Initial stage of collecting materials and patients' clinical data, each patient will undergoes strict follow up period to reveal the clinical, laboratory and radiological response. The procedures are to be approved by the institutional ethical committee.

Detailed description

This search will focus on patients with COVID 19 infection this study is a prospective cohort study based on the analysis of response in comparative panel between two arm Nitazoxanide, Ribavirin and Ivermectin plus Zinc arm and other arm without any intervention as regards the safety and efficacy and cost effective result. Two years duration of the project would be enough to cover the stages of the work as shown below in the time plan. Initial stage of collecting materials and patients' clinical data, each patient will undergoes strict follow up period to reveal the clinical, laboratory and radiological response. The procedures are to be approved by the institutional ethical committee.

Conditions

Interventions

TypeNameDescription
DRUGIvermectin,ribavirin ,nitazoxanide and zincoral intake of the 3 drugs ivermectin ,ribavirin and nitazoxanide plus zinc

Timeline

Start date
2021-04-01
Primary completion
2022-11-01
Completion
2022-12-01
First posted
2021-07-13
Last updated
2021-07-13

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04959786. Inclusion in this directory is not an endorsement.